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Characteristics of Tumor 
Infiltrating Lymphocyte and 
Circulating Lymphocyte 
Repertoires in Pancreatic Cancer 
by the Sequencing of T Cell 
Receptors
Xueli Bai1,2,*, Qi Zhang1,2,*, Song Wu3,4,*, Xiaoyu Zhang1, Mingbang Wang5, Fusheng He5, 
Tao Wei1, Jiaqi Yang1, Yu Lou1, Zhiming Cai3 & Tingbo Liang1,2,6
Pancreatic cancer has a poor prognosis and few effective treatments. The failure of treatment is 
partially due to the high heterogeneity of cancer cells within the tumor. T cells target and kill cancer 
cells by the specific recognition of cancer-associated antigens. In this study, T cells from primary 
tumor and blood of sixteen patients with pancreatic cancer were characterized by deep sequencing. 
T cells from blood of another eight healthy volunteers were also studied as controls. By analyzing 
the complementary determining region 3 (CDR3) gene sequence, we found no significant differences 
in the T cell receptor (TCR) repertoires between patients and healthy controls. Types and length of 
CDR3 were similar among groups. However, two clusters of patients were identified according to the 
degree of CDR3 overlap within tumor sample group. In addition, clonotypes with low frequencies 
were found in significantly higher numbers in primary pancreatic tumors compared to blood samples 
from patients and healthy controls. This study is the first to characterize the TCR repertoires of 
pancreatic cancers in both primary tumors and matched blood samples. The results imply that 
specific types of pancreatic cancer share potentially important immunological characteristics.
Pancreatic cancer is one of the most deadly malignant diseases, with a 5-year survival rate of only 6%1. 
No efficient therapeutic strategies have been developed to date in most cases. Extensive efforts have been 
made for decades to find specific targets in pancreatic cancer2. Immune cells, such as CD8+ T cells, 
can naturally remove cancer cells, which implies that certain subclones specifically recognize cancer 
cells by specific interactions with the T-cell receptor (TCR) and tumor-associated peptides. These T cell 
subclones may contribute significantly to the efficacy of anti-cancer immunotherapy including immune 
checkpoint blockades3 and chimeric antigen receptor T cell-based therapeutics4.
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T cells can be classified into two groups in patients with cancer: namely, tumor-infiltrating T cells and 
circulating T cells. These two components of the T cell repertoire are associated with each other but have 
distinct distributions of subclones, as well as different clinical significance5. It has been well documented 
that the number or proportion of tumor infiltrating lymphocytes (TILs) is associated with a better prog-
nosis in various types of cancer6. However, cancer cells can find ways to escape the immune response by 
exhausting or inactivating TILs7. It is therefore important to identify the T cell subclones that can kill 
cancer cells efficiently, and attempt to enhance them by different strategies.
TILs are exposed to the changing tumor microenvironment which is anisotropic in position and 
changes as tumor progresses8. Heterogeneity in cancer has been partially investigated through single 
cell sequencing of circulating tumor cells9. The TCR repertoire, from another perspective, shows exten-
sive heterogeneity in solid cancers, including pancreatic cancer10. From the results of high-throughput 
sequencing, investigators can now analyze the TCR repertoire and identify T cell subclones11. The TCR 
is responsible for T cell specificity, and is composed of two polypeptide chains in either an α β type or a 
γ δ type12. The complementary determining region 3 (CDR3) of the β chain further determines the anti-
genic specificity of T cells. CDR3 includes variable (V), diversity (D), and joining (J) regions encoded by 
the corresponding V, D, and J genes. The rearrangement of the V, D, and J regions ensures that CDR3 
has a high potential for diversity13, and makes it possible for T cells to target any antigens from either 
endogenous or exogenous sources14. Hence, sequencing the TCR repertoire is an accurate method to 
assess the immune response status of cancer patients.
High-throughput sequencing has been used to define T cell repertoires in blood samples of healthy 
individuals as well as tumor samples15. Most related studies have focused on different tumor sites to 
determine the heterogeneity or homogeneity of the tumor16,17. However, no reports to date have been 
published regarding pancreatic cancer, and few studies have emphasized the correlation between TILs 
and circulating T cells with regards to their TCR repertoires. In this study, we investigated the T cell rep-
ertoire in patients with pancreatic cancer (both blood and tumor samples) as well as those of healthy con-
trol individuals using high-throughput sequencing. These results deepen our understanding of immune 
system responses in patients with pancreatic cancer.
Results
An Average of 18 (range, 13 to 36) million sequencing reads were acquired from each sample in our 
cohort. The numbers of clonotypes were 93,925 ± 32,490, 76,093 ± 34,020, and 93,527 ± 9,392 in the pan-
creatic cancer tissue (PCT), pancreatic cancer blood (PCB), and healthy volunteer blood (HVB) groups, 
respectively (Table S1). The numbers of unique peptides detected were 69,467 ± 27,035, 62,162 ± 30,135, 
and 70,265 ± 6,937 in the PCT, PCB, and HVB groups, respectively. The total numbers and types of 
CDR3 were at the same level in all groups, although samples from the patients showed a higher level of 
diversity within the two groups (Fig. 1).
Abundance of the TCRβ CDR3 genes transcripts. We analyzed the highly expressed V and J gene 
segments, as well as the V-J gene pair, in all three groups, respectively. The top-20 genes expressed in each 
sample are listed in Fig. 2. Similar patterns were found in all these samples, and no significant difference 
was detected among the three groups. In particular, for the V gene, the TRBV20-1 and TRBV2 variants 
were commonly overexpressed in all samples (Fig.  2), while for the J gene, the TRBJ2-7 and TRBJ2-1 
Figure 1. Types and numbers of complementary determining region 3 (CDR3) in each group. Types 
and numbers of CDR3 were similar among groups; however, levels of diversity seemed higher in tissue and 
blood samples from patients compared to blood samples from healthy controls.
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were the most abundant variants (Fig. S1). In addition, the TRBV20-1;TRBJ2-7 and TRBV20-1;TRBJ2-1 
were the most highly expressed gene pairs in these samples.
To study the relationship between TCR repertoires in the tumor and blood samples in the 16 patients, 
we performed Wilcoxon rank sum tests to assess the VJ pairs detected. Two VJ pairs (TRBV9:TRBJ2-1 
and TRBV20-1:TRBJ1-6) were found with significantly higher levels of expression (Fig.  3). Of note, 
TRBV20-1 and TRBJ2-1 have been reported as the highest expressed V and J gene variants, respectively, 
in healthy individuals13,18.
Diversities of TCR repertoire in different groups. We used the inverse Simpson’s index to measure 
the diversity levels of the TCR repertoire in different groups, and no significant differences were found 
among the groups (Fig.  4). Moreover, we assessed the diversity of CDR3 by analyzing the transcript 
length distribution. The length of CDR3 was mainly between 39–45 base pairs (bp), and there was no 
significant difference with regards to the length distribution between groups (Fig. 5).
Figure 2. The top-20 expressed gene of the V gene segments in each group. No significant differences 
were detected between groups. The TRBV20-1 and TRBV2 variants were the most frequent in most samples.
Figure 3. The VJ pairs compared in tumor tissue and blood samples from the 16 patients. Wilcoxon 
rank sum tests were performed to assess each VJ pair, and P < 0.001 was considered as significant. The 
TRBV9:TRBJ2-1 and TRBV20-1:TRBJ1-6 were found significantly higher.
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TCR repertoires overlap within and between samples. To compare the similarity of TCR reper-
toires between tumor tissue and blood samples from patients, and between blood samples from patients 
and controls, we calculated the rate of overlap (Fig.  6a) and further transformed the data into a fuzzy 
heat map (Fig.  6b). Two significant clusters could be identified in the PCT group, which suggested a 
strong degree of similarity of the TCR repertoire in certain patients with pancreatic cancer. The two 
clusters had similar amounts of TILs (1.8 × 107 ± 1.1 × 106 vs. 2.0 × 107 ± 5.9 × 106); however, one cluster 
had significantly higher diversity of TILs than the other (8.1 × 104 ± 1.8 × 104 vs. 1.1 × 105 ± 2.9 × 104, 
P < 0.05; Fig. S2). No other demographic or clinicopathologic parameters such as lymph node metastasis 
and fibrotic response were found statistically different between the two clusters. Meanwhile, a weaker 
degree of similarity could also be found in the PCB group. Importantly, both the PCT and PCB groups 
showed little overlap with the results from the HVB group, which implied that the immune status of 
patients with pancreatic cancer had been changed.
To further explore the potential common CDR3 in PCT group, we performed a phylogenetic relation-
ship analysis in all CDR3 transcripts that contributed to the overlap between samples, but no significant 
clusters were determined among these CDR3 regions (Fig. S3). However, we screened all the sequences 
and found 15 CDR3 sequences and 30 amino acid sequences were rare in the healthy volunteers but 
Figure 4. Diversity of TCR repertoires was similar among groups. Inverse Simpson’s diversity index 
was used to assess the diversity of TCR repertoires, and no significant differences were found among these 
groups.
Figure 5. Complementary determining region 3 (CDR3) length usage difference was not detected in 
groups. The median lengths were 42 base pairs and normal distribution was found in all three groups.
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were shared by more than 7 patients (in both tumor tissue and blood samples; Table S2). Notably, gene 
expression products of all the 15 CDR3 sequences were included in the 30 amino acid sequences iden-
tified (Table S2).
Different clonotype abundance ratios of CDR3. CDR3 clonotypes were further classified into five 
groups according to their abundance, and divided by 0.001%, 0.01%, or 1% of 106 analyzed T cells 
(Table  1). The small and medium groups occupied between 80% and 90% of clonotypes in the PCT 
samples. The hyper-expanded and large groups of clonotypes showed insignificant differences between 
groups (Fig. S4). However, there was a lower proportion of the medium clonotypes and a higher propor-
tion of the small clonotypes in the PCT group compared to those in the PCB and HVB groups (Fig. 7).
Discussion
Tumor heterogeneity is one the primary obstacles of treatment, and is responsible for drug resistance 
and the recurrence of solid cancers, including pancreatic cancer19,20. Theoretically, the clonal evolution 
model assumes a branched evolution of cancer and provides an explanation for the generation of heter-
ogeneity21. Previous reports have confirmed a high level of heterogeneity within a tumor22. Recently, the 
TIL TCR repertoire has been investigated in many types of solid cancer, and has verified that an aston-
ishing amount of heterogeneity can occur in different regions of one single slide of ovarian cancer11,16, 
and renal cell carcinoma17. To our knowledge, this is the first report regarding the TCR repertoire in 
pancreatic cancer.
Two VJ pairs were underlined by comparing TCR repertoires between tumor and blood samples; 
however, some of their components are frequently found in healthy individuals. This finding indicated 
the effect of common infections, such as Epstein-Barr virus. Given the poor prognosis of pancreatic can-
cer, the high frequency of these V and J segments found in our study (Fig. 2) further suggests that they 
are unlikely to be associated with the specific antigens shared between healthy individuals and patients 
with pancreatic cancer.
Although we have not identified certain subclones of T cells that have specifically expanded and 
shared in all pancreatic cancer patients, we indeed found a similarity in patients compared to controls. 
Figure 6. Overlap of TCR repertoires in patients. (a) The similarity of TCR repertoires from the 16 
patients and 8 healthy controls was analyzed. Healthy individuals formed an independent cluster. Tumor 
tissue and blood samples from patients were mixed together but some clusters were formed. (b) Fussy heat 
map showed two clusters in tumor tissue and blood samples from the patients.
Clone type Clone size
Rare Single-cell events




Table 1.  Definitions of clonotype groups classified according to frequency.
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However, the relatively higher similarity determined in both the tumors and blood samples of patients 
compared to the healthy controls suggested that some subclones commonly exist in pancreatic cancer. 
These subclones might target the tumor-associated antigens. Given the finding that there was no dif-
ference in the subclones with higher levels of abundance, these subclones were probably less abundant. 
The inefficiency of expansion of some of these subclones might be a result of tumor-induced immune 
suppression, and could partially explain why pancreatic cancer escapes elimination by the immune sys-
tem. In addition, a greater degree of overlap was found in the TIL samples than in the blood, which 
suggested that there were true differences between the TCR repertoires of TILs and circulating T cells. 
Such differences have already been determined in various other types of cancer5,23. Our results confirmed 
the distinctiveness of TILs in pancreatic cancer compared to circulating T cells, and indicates that specific 
antigens with pancreatic tumors are encountered by the immune system.
In the current limited dataset, we failed to identify specific CDR3 transcripts with regards to the 
potential homogeneity of pancreatic cancer. This finding may have been partially due to the high level of 
heterogeneity of this type of cancer, as well as the diversity of the basic congenital TCR repertoires among 
individuals. Another reason is that T cells, unlike B cells that consistently enhance antibody affinities by 
evolving, undergo clonal selection and require antigen-presenting cells to provide processed antigens24. 
This makes the study of T cells more difficult. Efficient approaches are currently unavailable, which limits 
the functional analysis of the CDR3 regions.
However, given the heterogeneity of TCR repertoires among different individuals, we identified some 
CDR3 and amino acid sequences shared in some patients. This finding could still be meaningful since 
it seemed hopeless to identify the common TCR in all patients. The 15 CDR3 sequences and corre-
sponding amino acid sequences also suggested a subgroup of patients from a molecular point of view, 
although we did not find demographic or clinicopathological characteristics these patients shared in 
common when the patients were grouped by certain sequence. It could be valuable to make an in-depth 
analysis of these identified TCR gene and amino acid sequences since some of them were associated 
with tumor-associating antigens and might be helpful to control tumors. For instance, mesothelin was 
found with high expression in pancreatic cancer and listeria monocytogenes-expressing mesothelin boost 
vaccine has been recently reported to increase clinical response and survival in pancreatic patients25. 
Other tumor-associated antigens like carbohydrate antigen 19-9 was also used as a target for engineered 
T cells26. Thus, further study on these sequences using TCR T cells or chimeric antigen receptor T cells 
may be valuable to test their anti-tumor effects.
Mutations accumulated as the tumor evolves. Low-frequency subclones may regulate the development 
of the dominant subclone within cancer27. Although no evidence showed the correlation between the 
frequency of cancer cell subclones and the frequency of according T cell subclones, the frequency distri-
bution of T cell clonotypes may implicate the complexity of heterogeneity within the tumor. With regards 
to the different sizes of clonotypes, we did not analyze the rare ones as they were quite infrequent and 
our method was insufficient to ascertain the results from single cells. Although most unselected T cell 
subclones were found at a low level, the impressive degree of overlap particularly in the PCT group in 
particular suggested that some of the subclones were specific to pancreatic cancer. On the other hand, the 
clonotypes with increased levels of frequency reflected the large degree of immune stress within tumors, 
which could manifest as increased numbers of novel antigens that resulted from genetic mutations within 
cancer cells. Additionally, the reduced frequency of clonotypes with a median size may result from a 
Figure 7. Differences in different clonotypes in the three groups. T cell clonotypes were categorized 
by different frequencies. (a) Tumor tissue samples showed significantly lower levels of medium frequency 
(0.001%–0.01%) clonotype compared to blood samples from the patients and healthy controls. (b) Tumor 
tissue samples showed significantly lower levels of medium frequency (< 0.001%) clonotype compared to 
blood samples from the patients and healthy controls. ****P < 0.0001, *****P < 10−5, **********P < 10−10.
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seesaw effect with small clonotypes. Besides, the significantly increased median size might be indicative 
of T regulatory cells within tumors.
In general, there was no significant difference between patients with pancreatic cancer and healthy 
volunteers with regards to their TCR repertoires. No differences were found either between the samples 
of tumor tissue and the blood samples from patients. However, some unidentified CDR3 regions of T 
cells were indeed associated with pancreatic cancer. Unfortunately no relevant databases exist currently 
to assess these. We also confirmed the heterogeneity of pancreatic cancer, and through the characteristic 
distribution of clonotypes, we hypothesize that the cancer cells undergo immunological adaption and 
therefore escape from local immune surveillance.
Methods
Patients and sample collection. This study enrolled 16 patients with pancreatic ductal adenocar-
cinoma and 8 healthy volunteers as controls. All patients had been diagnosed by tissue pathology, and 
all had undergone surgery at the Second Affiliated Hospital, Zhejiang University School of Medicine 
between July 2012 and June 2013. None of these patients had undergone preoperative chemotherapy or 
radiotherapy. The basic demographic information of the patients is shown in Table 2.
Tumor tissue samples were placed in liquid nitrogen within 30 min after excision, and stored at − 80 °C 
until analysis. The matched peripheral blood samples of the patients were collected into K2EDTA tubes 
before surgery, and centrifuged at 1,300 g for 15 min at 4 °C within 16 hours after surgery. DNA was 
extracted from peripheral blood mononuclear cells, which were isolated using lymphocyte separation 
medium (Beyotime Biotechnology, Shanghai, China). The peripheral blood samples of healthy volunteers 
were collected in the same method as described above. All samples were classified into three groups: 
HCT, HCB, and HVB. The protocol of this study was in accordance with the Declaration of Helsinki, 
and was approved by the Human Ethic Committee of the Second Affiliated Hospital, Zhejiang University 
School of Medicine. Written informed consent was acquired from all patients and volunteers.
Multiple-PCR and high-throughput sequencing. We used multiple-polymerase chain reaction 
(PCR) and 5′ rapid-amplification of cDNA ends (RACE) to capture CDR3 regions using a specifically 
designed set of primers for the TCRβ CDR3 V and J regions (BGI, Shenzhen, China; Table S3). The cap-
tured regions were then sequenced on high-throughput sequencing platform (Hiseq2000; Illumina, San 
Diego, CA, USA). Using the alignment tool (BGI), we filtered the sequencing background and aligned 
the raw data to V and J gene segments in the international ImMunoGeneTics (IMGT®) database28. 
Several methods were used to eliminate PCR and sequencing errors. (1) Aquirement of reads with appro-
priate paired-ends (PE): reads without ends or with ends shorter than 50 bp were considered appropriate, 
with PE1 ≥ 60 bp and PE2 ≥ 50 bp. (2) Elinimate low-quality reads: the proportion of unidentified bases 
in the sequence should be less than 5%, and the average base quality should be never lower than 15. 
Bases at the end of reads with base quality less than 10 were deleted. (3) Merge paired-ends into contigs: 
PE1 and PE2 of reads with paired-ends should have an overlap of 10 bp or more, and the mismatch in 
the overlap region should be less than 2.
CDR3 sequence analysis. We analyzed the V and J gene frequency, frequency distribution of clono-
types, and the number of total peptide sequences for CDR3, in addition to the total sequence numbers 
of the V and J gene segments in each sample. To assess the similarity and differences in the TCRβ rep-
ertoires among the three groups of samples, we calculated the inverse Simpson’s index of diversity, the 
metric overlap of TCRβ CDR3, and the abundance ratios of different clonotypes29.
Screen of cancer specific TCR gene and amino acid sequences. We defined a sequence found in 
more than 7 samples in both PCT and PCB groups and less than 3 samples in HVB group as a candidate 
for pancreatic cancer specific TCR gene or amino acid sequence. Expression of the certain sequence was 
calculated as the ratio of reads of the certain sequence and the total reads.
Variable Patients (n = 16)
Sex
 Male: female 11: 5
Age, median (range), year 63 (39–78)
Tumor stage
 I: II: III: IV 1: 10: 3: 2
Lymph node involvement
 Positive: negative unknown 7: 8: 1
Table 2.  Demographic data for the patients in this study.
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Statistical analysis. Diversity levels and differences among groups were analyzed by one-way 
ANOVA, and P-values less than 0.05 were considered as statistically significant. For VJ pair comparison 
between tumors and blood samples of patients, Wilcoxon rank sum tests were performed and P-values 
less than 0.001 were considered as statistically significant.
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